within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EF01_Palbociclib;
model Palbociclib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EF01;

  annotation(Documentation(
    info ="<html><body><p>Palbociclib is an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is an FDA- and EMA-approved antineoplastic agent administered in combination with endocrine therapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult advanced breast cancer patients, both female and male (predominantly female), mean age ~57 years, oral dosing.</p><h4>References</h4><ol><li><p>Royer, B, et al., &amp; Schmitt, A (2021). Population Pharmacokinetics of Palbociclib in aReal-World Situation. <i>Pharmaceuticals (Basel, Switzerland)</i> 14(3) –. DOI:<a href=&quot;https://doi.org/10.3390/ph14030181&quot;>10.3390/ph14030181</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33668400/&quot;>https://pubmed.ncbi.nlm.nih.gov/33668400</a></p></li><li><p>Yu, Y, et al., &amp; Wang, D (2020). Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function. <i>Cancer chemotherapy and pharmacology</i> 86(6) 701–710. DOI:<a href=&quot;https://doi.org/10.1007/s00280-020-04163-4&quot;>10.1007/s00280-020-04163-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33037918/&quot;>https://pubmed.ncbi.nlm.nih.gov/33037918</a></p></li><li><p>Cortés, J, et al., &amp; Bardia, A (2024). Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 42(22) 2680–2690. DOI:<a href=&quot;https://doi.org/10.1200/JCO.23.02036&quot;>10.1200/JCO.23.02036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38889373/&quot;>https://pubmed.ncbi.nlm.nih.gov/38889373</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Palbociclib;
